Truxima®

Truxima® is a biosimilar monoclonal antibody designed to target the CD20 antigen. It was developed by Celltrion Healthcare for use in oncology, hematology and rheumatology, and received market approval in Switzerland in 2019. It is a Class A drug that must be stored between 2°C and 8°C. Truxima® is administered intravenously.
Truxima-rituximab 100mg and 500mg

Grasustek®

Grasustek® is a biosimilar granulocyte colony stimulating factor used in oncology. Developed by USV Private Limited, it was approved for sale in Switzerland in 2021. It is a Class A drug that must be stored between 2°C and 8°C. Grasustek® can be self-administered subcutaneously.
Grasustek-pegfilgrastim 6mg

Herzuma®

Herzuma® is a biosimilar monoclonal antibody designed to target HER2. It was developed by Celltrion Healthcare for use in oncology and received market approval in Switzerland in 2021. It is a Class A drug that must be stored between 2°C and 8°C. Herzuma® is administered intravenously.
Herzuma-trastuzumab 150mg and 440mg

Speak with one of our experts
If you are a Healthcare Professional, our team will be happy to have a chat with you.

Cédric Ruscio
Commercial Manager Oncology Switzerland +41 79 278 02 81 cedric.ruscio@iqone-healthcare.com